We have detected significant local reductions in inflammatory cell responses and vasculopathy development with either GAG or CCR2 deficiency or after treatment with viral chemokine modulating proteins (CMPs) targeting GAG or receptor binding. The gene discussed is CCR2; the disease is vascular disorder.